MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 90 filers reported holding MARINUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,748,673 | -25.0% | 2,577,475 | +1.2% | 0.00% | 0.0% |
| Q2 2023 | $27,652,188 | +83.4% | 2,546,242 | +16.5% | 0.00% | – |
| Q1 2023 | $15,074,733 | +90.1% | 2,184,744 | +9.7% | 0.00% | – |
| Q4 2022 | $7,928,514 | -29.5% | 1,992,089 | +17.8% | 0.00% | – |
| Q3 2022 | $11,248,000 | +38.8% | 1,691,370 | +1.0% | 0.00% | – |
| Q2 2022 | $8,105,000 | -48.9% | 1,674,558 | -1.3% | 0.00% | – |
| Q1 2022 | $15,864,000 | -21.2% | 1,696,675 | +0.2% | 0.00% | – |
| Q4 2021 | $20,126,000 | +4.3% | 1,694,118 | -0.1% | 0.00% | – |
| Q3 2021 | $19,303,000 | -37.7% | 1,696,244 | -1.7% | 0.00% | -100.0% |
| Q2 2021 | $30,961,000 | +17.4% | 1,725,750 | +1.3% | 0.00% | 0.0% |
| Q1 2021 | $26,362,000 | +36.9% | 1,702,989 | +7.9% | 0.00% | 0.0% |
| Q4 2020 | $19,253,000 | +18.3% | 1,578,084 | +24.6% | 0.00% | 0.0% |
| Q3 2020 | $16,275,000 | – | 1,266,572 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |